ScripOne of the reasons that venture capital investment in biopharmaceutical companies is booming is because of mega-deals exceeding $100m in a single round – often at the Series A level – and the trend co
ScripCelgene Corp. 's aggressive deal-making strategy could pay off in a big way over the next several years, bringing in billions of dollars in annual sales from new drugs to diversify revenue beyond its
In VivoIN VITRO DIAGNOSTICS Alliances Angle PLC Qiagen NV Angle PLC and Qiagen NV will co-promote each other’s liquid biopsy solutions for cancer detection. (Sep.) To the deal Angle contributes its
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in